Nitya Rajeshuni

Dr. Nitya Rajeshuni

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Siyan YiSiyan Yi
Siyan Yi
EYEsabelle Lo Yan Yam
Esabelle Lo Yan Yam
KCKochukoshy Cheruvettolil
Kochukoshy Cheruvettolil
ELEleni Linos
Eleni Linos
AGAnshika Gupta
Anshika Gupta
KEKaren Eggleston
Karen Eggleston
Digital health innovations have emerged globally as a transformative force for addressing health system challenges, particularly in resource-constrained settings. The COVID-19 pandemic underscored the critical importance of these innovations for enhancing public health. In South and Southeast Asia, a region known for its cultural diversity and complex health care landscape, digital health innovations present a dynamic interplay of challenges and opportunities. We advocate for ongoing research built into system development and an evidence-based strategy focusing on designing and scaling national digital health infrastructures combined with a vibrant ecosystem or “marketplace” of local experiments generating shared experience about what works in which settings. As the global digital health revolution unfolds, the perspectives drawn from South and Southeast Asia—including the importance of local partnerships—may provide valuable insights for shaping future strategies and informing similar initiatives in low- and middle-income countries, contributing to effective digital health strategies across diverse global health contexts.

1 March 2020 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
BTBrandon Turner
Brandon Turner
NRNitya Rajeshuni
Nitya Rajeshuni
ETElaine M. Tran
Elaine M. Tran
CLCassie A. Ludwig
Cassie A. Ludwig
ZTZujaja Tauqeer
Zujaja Tauqeer
SPSuzann Pershing
Suzann Pershing

12 July 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
NRNitya Rajeshuni
Nitya Rajeshuni
EJEmily E. Johnston
Emily E. Johnston
OSOlga Saynina
Olga Saynina
LSLee M. Sanders
Lee M. Sanders
LCLisa J. Chamberlain
Lisa J. Chamberlain

24 June 2025 in The American Surgeon™
Verified
Journal Article
Closed access
STSeth Tivakaran
Seth Tivakaran
JRJulia L. Raghu
Julia L. Raghu
JLJeff C. K. Leung
Jeff C. K. Leung
KTKing Sum Tong
King Sum Tong
NPNicholas L. Panyanouvong
Nicholas L. Panyanouvong
JVJeffrey B. Velotta
Jeffrey B. Velotta
Background: Lung cancer is the leading cause of cancer-related deaths worldwide in Asian Americans (AsA), yet AsA lung cancer screening (LCS) rates are unknown. We examined LCS rates in AsA within Kaiser Permanente Northern California (KPNC), a large integrated healthcare system where LCS is a member benefit. The California LCS rate is 0.7%. Methods: This cohort study analyzed KPNC 2015-2022 electronic health records. Lung cancer screening rates were compared among AsA subgroups, controlling for sociodemographics, considering both more restrictive 2013 (n = 2,273) and more inclusive 2021 (n = 5,823) United States Preventive Services Task Force (USPSTF) LCS guidelines, which differ by age range and years post-smoking cessation. Results: Overall KPNC LCS rates for eligible AsA patients were 4.3% and 2.7% using USPSTF 2013 and 2021 guidelines, respectively. Lung cancer screening rates varied by AsA subgroup. Under 2021 guidelines, Chinese (4.0%) were screened more than Korean (3.57%), Southeast Asian (3.52%), Japanese (3.19%), Asian (Other) (2.28%), Pacific Islander (1.91%), and Filipino (1.55%). Under 2013 guidelines, Southeast Asian (6.54%) were screened more than Chinese (6.51%), Japanese (5.36%), Asian (Other) (3.95%), and Filipino (1.93%). Discussion: This is the first study to demonstrate significant heterogeneity in LCS rates for disaggregated AsA subgroups. Kaiser Permanente Northern California LCS rates were 4× California rates. When payment alone is not a care barrier, systemic and culturally sensitive interventions are necessary to increase overall LCS screening rates and address population-specific disparities.

26 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BKBani Kaur
Bani Kaur
ABAvinav Biswas
Avinav Biswas
TCTyler Christian Chervo
Tyler Christian Chervo
WAWoo Jin Ahn
Woo Jin Ahn
SGShangzi Gao
Shangzi Gao
JVJeffrey Velotta
Jeffrey Velotta
Background: Despite decline in lung cancer in the U.S., lung cancer among never-smoking Asian American (AsA) women is rising, and subgroup aggregation obscures heterogeneity. We compared primary lung cancer prevalence across disaggregated AsA subgroups and examined associations with risk factors such as personal- and family-cancer histories versus non-Hispanic Whites (NHW). Methods: This cross-sectional study analyzed electronic health records of AsA women (≥18) in a large Northern California health system (2010–2022). Lung cancer cases were obtained from the hospital registry and categorized by smoking status and self-reported ethnicity. Adjusted prevalence ratios (aPRs) were estimated using targeted maximum likelihood estimation, accounting for sociodemographic, smoking, and clinical covariates. Results: Among 1,843,119 AsA women, 8,651 had primary lung cancer; 2,429 were never-smokers. In never-smokers, aPRs and 95% confidence intervals versus age-matched NHW were: Chinese (3.36, [3.20–3.53]), Filipino (2.68, [2.55–2.82]), Vietnamese (2.07, [1.96–2.18]), Japanese (1.99, [1.89–2.10]), Korean (1.90, [1.80–2.00]); Other Asian (0.35, [0.33–0.37]). Personal cancer-history reflected an increase in prevalence among Korean patients (2.91, [2.76–3.06]) while family cancer-history demonstrated increased prevalence among Chinese patients (1.51, [1.42–1.60]). Among women with uterine cancer, Chinese patients had higher lung-cancer prevalence than NHW (1.91, [1.58–2.31]). Conclusions: Never-smoking disaggregated AsA women show heterogeneous lung cancer prevalence, with higher prevalence in Korean women with personal cancer-history and in Chinese women with family cancer-history compared with NHW, supporting history-informed and ethnic-specific lung cancer screenings.

1 August 2023 in NeoReviews
Verified
Journal Article
Closed access
PDF file
LLLeora Lieberman
Leora Lieberman
NRNitya Rajeshuni
Nitya Rajeshuni
ESEvan Shirey
Evan Shirey
YFYasaman Fatemi
Yasaman Fatemi
ACAnna Costello
Anna Costello